Ignite Creation Date:
2024-05-05 @ 10:02 PM
Last Modification Date:
2024-10-26 @ 10:12 AM
Study NCT ID:
NCT01015521
Status:
WITHDRAWN
Last Update Posted:
2010-11-03
First Post:
2009-11-16
Brief Title:
Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
Sponsor:
Tigris Pharmaceuticals
Organization:
Tigris Pharmaceuticals
Study Overview
Official Title:
A Two-Arm Open Label Phase II Study of AFP464 Aminoflavone Prodrug in Previously-treated ER-positive or Triple-negative Breast Cancer Patients
Status:
WITHDRAWN
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was not initiated as planned
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None